<DOC>
	<DOCNO>NCT00774982</DOCNO>
	<brief_summary>The study conduct evaluate pharmacokinetic parameter ( Cmax , Tmax AUC ) new delay release , lower dose , 40 mg 6MP test formulation compare standard 6MP ( 100 mg Purinethol ) 12 patient Crohn 's Disease . The study undertaken prove new test formulation indeed delayed-release target ileum , level 6MP blood follow local absorption lower see follow standard Purinethol dosing . This result low , safe mercaptopurine dosing , allow uninterrupted treatment few side effect .</brief_summary>
	<brief_title>Pilot Comparative Bioavailability Study 6Mercaptopurine ( Delayed Release vs. Purinethol ) Crohns Disease Patients</brief_title>
	<detailed_description>A new delayed release , faster-disintegrating , low dose oral formulation 6 mercaptopurine target delivery ileum ( commonly effect area Crohns Disease ( CD ) bowel involvement ) , develop show effective three efficacy parameter evaluate small group Crohns Disease patient . Twelve week daily treatment once-nightly dose 40 mg local 6MP result : ( 1 ) induce clinical remission ( CDAI score 150 early week 2 4 ) , ( 2 ) effect local mucosal healing ( evidence lower CDEIS score descriptive conolonoscopy report ) ( 3 ) reduce systemic immunological score ( lower IFN-gamma Elispot level ) . The current study undertaken confirm , via pharmacokinetic profile ( Cmax , AUC Tmax ) , underlie premise above-noted clinical feasibility study . This PK study conduct establish ( 1 ) The delayed release test formulation delivers drug distally low intestine ( 2 ) The delayed release test formulation potential reduce systemic toxicity . The first aspect establish compare Tmax delay release test formulation vs. oral Purinethol , second aspect establish compare Cmax AUC 40 mg test dose vs. standard 100 mg Purinethol . It anticipate delayed release test formulation exhibit later Tmax reduce Cmax AUC compare reference Purinethol . Additionally , immunology test measure effect new 6MP formulation immunological FACS analysis perform peripheral blood lymphocytes 0 , 12 24 hour post-dosing formualtion . Lymphocytes tested surface marker expression ( ex : CD3 , CD4 , CD8 , CD25 , NKT , etc . ) , anticipate result great lower immune parameter even 1 dose 40 mg delay release test drug , compare 100 mg Purinethol .</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<criteria>12 male nonpregnant female , age 1850 year , Crohns Disease ( CDAI 200 ) , nonsmoking . Crohns Disease diagnosis via colonoscopy biopsy within past 12 year No CD medication allow study 5ASA symptomatic relief ( antidiarrheal ) Screening lab test : HGB &gt; = 8.5 g/dl , platelet &gt; = 100,000/mm3 , WBC : 350012000/mm3 , serum albumin 2.5 g/dl , amylase , lipase total bilirubin within normal limit ; ALT , AST , alkaline phosphatase 1.5 x normal limit No 2 bowel movements/24 hour period week prior screen No patient methotrexate , cyclosporine , antiTNF alpha , antineoplastic within 3 month study start NO fistulizing CD isolate small bowle CD No symptomatic stenosis ileal stricture , xray evidnece fibrosed bowel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Crohns Disease</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Local Targeted Delivery Ileum</keyword>
	<keyword>Delayed Release</keyword>
	<keyword>Immunology Measurements</keyword>
	<keyword>Pharmacokinetics Crohns Disease Patients</keyword>
</DOC>